Enhanced Response to Enzyme Replacement Therapy in Pompe Disease after the Induction of Immune Tolerance

This publication has 41 references indexed in Scilit:

• Muscle as a Target for Supplementary Factor IX Gene Transfer
  Human Gene Therapy, 2007
• Enhanced Efficacy of an AAV Vector Encoding Chimeric, Highly Secreted Acid α-Glucosidase in Glycogen Storage Disease Type II
  Molecular Therapy, 2006
• Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe disease
  The Journal of Pediatrics, 2006
• Biology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman Primates
  Molecular Therapy, 2006
• Integration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors
  Annual Review of Genetics, 2004
• Therapeutic Levels of Factor IX Expression Using a Muscle-Specific Promoter and Adeno-Associated Virus Serotype 1 Vector
  Human Gene Therapy, 2004
• Packaging of an AAV vector encoding human acid α-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector
  Molecular Therapy, 2003
• Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle
  Journal of Virology, 2003
• Muscle-Directed Gene Transfer and Transient Immune Suppression Result in Sustained Partial Correction of Canine Hemophilia B Caused by a Null Mutation
  Molecular Therapy, 2001
• Sustained Expression of Therapeutic Level of Factor IX in Hemophilia B Dogs by AAV-Mediated Gene Therapy in Liver
  Molecular Therapy, 2000